Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Imatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 20/20 | 0.96 |
| ▸ | BCR known ✓ | P11274 | 14/20 | 0.96 |
| ▸ | KIT known ✓ | P10721 | 12/20 | 0.96 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 0.96 |
| ▸ | ABL2 | P42684 | 7/20 | 0.96 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.96 |
| ▸ | LYN | P07948 | 3/20 | 0.96 |
| ▸ | SRC | P12931 | 2/20 | 0.96 |
| ▸ | SYK | P43405 | 2/20 | 0.96 |
| ▸ | PLK4 | O00444 | 1/20 | 0.96 |
| ▸ | DDX3X | O00571 | 1/20 | 0.96 |
| ▸ | GAK | O14976 | 1/20 | 0.96 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.96 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.96 |
| ▸ | CA12 | O43570 | 1/20 | 0.96 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.96 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.96 |
| ▸ | EGFR | P00533 | 1/20 | 0.96 |
| ▸ | CA1 | P00915 | 1/20 | 0.96 |
| ▸ | CA2 | P00918 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imatinib SCHEMBL29351601 | 0.98 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL3827 | 0.98 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL2236091 | 0.98 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL29355523 | 0.98 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Acetic Acid SCHEMBL3863232 | 0.97 | ABL1 (0.90) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL4078291 | 0.97 | ABL1 (0.96) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL529425 | 0.97 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL15201213 | 0.97 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL3138052 | 0.97 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL2929858 | 0.97 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112272669-A | Cross-linked pyrrolobenzodiazepine dimer (PBD) derivatives and conjugates thereof | 杭州多禧生物科技有限公司 | 2021-01-26 | — | — | CN | disclosed |
| EP-2829538-A1 | Polymorphic form of imatinib mesylate and process for its preparation | Sicor, Inc. (US) | 2015-01-28 | — | — | EP | disclosed |
| WO-2012090221-A1 | NOVEL SALTS OF IMATINIB | CADILA HEALTHCARE LIMITED (IN) | 2012-07-05 | — | — | WO | disclosed |
| US-8067421-B2 | Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α | SICOR INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-7977348-B2 | Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α | SICOR INC. (US) | 2011-07-12 | — | — | US | disclosed |
| EP-2311821-A1 | Polymorphic form of Imatinib mesylate and processes for its preparation | Sicor, Inc. (US) | 2011-04-20 | — | — | EP | disclosed |
| US-20090264438-A1 | Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form alpha | SICOR SOCIETÀ ITALIANA CORTICOSTEROIDI S.R.L (IT) | 2009-10-22 | — | — | US | disclosed |
| EP-1919893-A2 | POLYMORPHIC FORMS OF IMATINIB MESYLATE AND PROCESSES FOR THEIR PREPARATION AS WELL AS OF AMORPHOUS IMATINIB MESYLATE AND FORM ALPHA | Sicor, Inc. (US) | 2008-05-14 | — | — | EP | disclosed |
| US-20080090833-A1 | Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form alpha | SICOR SOCIETÀ ITALIANA CORTICOSTEROIDI S.R.L (IT) | 2008-04-17 | — | — | US | disclosed |
| WO-2007136510-A2 | POLYMORPHIC FORMS OF IMATINIB MESYLATE AND PROCESSES FOR THEIR PREPARATION AS WELL AS OF AMORPHOUS IMATINIB MESYLATE AND FORM ALPHA | SICOR INC. (US) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090833-A1 | Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form alpha | ABL1, ABL2, TP53 | ABL1 1/4885BCR 17/4885KIT 32/4885 |
| US-20090264438-A1 | Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form alpha | ABL1, ABL2, TP53 | ABL1 1/4885BCR 17/4885KIT 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.